Showing results (301-310 of 320) with videos related to

Sort By:
Pageof 32
Scientific Reports|June 15, 2022
HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinomaToru Nakamura, Tsuyoshi Hayashi, Yasutoshi Kimura, et al.
Modern Rheumatology|March 12, 2021
Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritisEiichi Tanaka, Yutaka Kawahito, Masataka Kohno, et al.
Journal of Contemporary Brachytherapy|March 27, 2023
HDR-brachytherapy for accelerated partial breast irradiation: Long-term experience from a Japanese institutionKen Yoshida, Tadayuki Kotsuma, Yuji Takaoka, et al.
Modern Rheumatology|March 21, 2024
Consensus statement on the management of late-onset rheumatoid arthritisMasayo Kojima, Takahiko Sugihara, Yutaka Kawahito, et al.
The Kurume Medical Journal|November 27, 2024
Validity of High-Dose-Rate Interstitial Brachytherapy as Monotherapy for Mobile Tongue Cancer in Terms of the Acute Mucosal ReactionHironori Akiyama, Ken Yoshida, Tadayuki Kotsuma, et al.
Arthritis Care & Research|July 24, 2015
Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational RegistriesSuzanne M M Verstappen, Johan Askling, Niklas Berglind, et al.
Modern Rheumatology|April 7, 2025
Comparative Clinical Practice of Juvenile Idiopathic Arthritis and Rheumatoid Arthritis in Adolescents and Young Adults: A Retrospective Cohort Study Using Japanese Health Insurance Claims Data (2016-2020)Takako Miyamae, Ryoko Sakai, Yuzaburo Inoue, et al.
Annals of the Rheumatic Diseases|December 2, 2015
How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registriesJohan Askling, Niklas Berglind, Stefan Franzen, et al.
Annals of the Rheumatic Diseases|February 10, 2016
Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular diseaseKaleb Michaud, Niklas Berglind, Stefan Franzén, et al.
Annals of the Rheumatic Diseases|October 21, 2019
Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trialYoshiya Tanaka, Koji Oba, Takao Koike, et al.
Pageof 32